Page 1 of 215
Boehringer Ingelheim
Risk Management Plan
Version 21.1
______________________________________________
Page 20 of 215
Empagliflozin
s00017688-52 
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 21.1
______________________________________________
Page 21 of 215
Empagliflozin
s00017688-52 
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 21.1
______________________________________________
Page 22 of 215
Empagliflozin
s00017688-52 
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 21.1
______________________________________________
Page 23 of 215
Empagliflozin
s00017688-52 
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 21.1
______________________________________________
Page 57 of 215
Empagliflozin
s00017688-52 
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 21.1
______________________________________________
Page 58 of 215
Empagliflozin
s00017688-52 
_______________________________________________________________________
Ingelheim 
Boehringer 
Risk Management 
Plan 
21.1 
Version 
Page 142 of215 
Empagliflozin 
sOOOl 7688-52 
MODULE SV POST-AUTHORISATION 
EXPERIENCE 
SV.1 
POST-AUTHORISATION EXPOSURE 
SV.1.1  Method used to calculate 
exposure 
The method used to estimate 
sales). 
tablets 
sold (ex-factory 
that each patient 
Assuming 
was treated 
is then divided 
further 
for 365.25 
by 365.25 
exposure 
patient 
lt was assumed 
was treated 
days as the therapy duration. 
the total patient 
to calculate 
in PY. 
exposure 
to the marketed 
that all tablets 
with 1 tablet 
dmg is based on the number of 
were used by the patients. 
per day ( defined daily dose ), and 
The total number of days of medication 
SV.1.2  Exposure 
cumulative 
exposure 
1 fotmulation 
cumulative 
Calculated 
As there is only 
patient 
applicable. 
15 319 021 PY for the period April 
2014 to April 2021. Marketing 
is not yet available. 
failure 
are presented 
for Jardiance, 
exposure 
by <lose and region 
a presentation 
to marketed 
figures 
(tablet) 
by this variable 
to be 
is not 
is estimated 
in the herui 
indication 
experience 
in the table below. 
Jardiance 
The overall 
SV.Table 
1 
Cumulative 
for Jardiance 
exposure 
(April 
from marketing 
experience 
by <lose and region 
2014 to April 2021) -T2DM indication 
Region/ 
Dose 
Tablet, 
10 mg 
Tablet, 
25 mg 
Total 
Cumulative 
[PY] 
exposure 
- - --
- - - -
- - - -
8 248 029
7 070 992
to the nearest 
PBRER, reporting 
integer 
18 Apr 2019 to 17 Apr 2021 (s00096926
interval 
-01], Table 7 
15 319 021
Total 
Note: All numbers 
Data source: 
Jardiance
/Synjardy 
are rom1ded 
Boehringer Ingelheim
Risk Management Plan
Version 21.1
_____________________________________
Page 213 of 215
Empagliflozin
s00017688-52 
________________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 21.1
_____________________________________
Page 214 of 215
Empagliflozin
s00017688-52 
________________________________________________________________________
